fda warning letters glp-1 compounders september 2025 news Warns Telehealth Firms Over Compounded FDA Drug Recalls and Warnings:

Typical Beginner Dosage 2040 mcg per day , administered once daily Injected subcutaneously (SQ) or intramuscularly (IM) Best injected post-workout on training days for maximum uptake Cycle length: 46 weeks , followed by equal time off Higher doses (50100 mcg) are used by advanced users but increase the risk of insulin resistance and IGF-related side effects

The groups were compared for body weight, fur condition, and walking status to confirm successful randomization

[DOI] [PMC free article] [PubMed] [Google Scholar] 66.Nader-Marta G, Molinelli C, Debien V, et al

As obese humans show lower circulating glucagon-like peptide-1 (GLP-1), similar to that of PYY, it has been thought that the resistance to this gut hormone contributes to the obesity

MBX 4291, dual GLP-1/GIP co-agonist prodrug designed for potential once-monthly dosing and improved tolerability in obesity Recent Highlights: In June 2026, MBX Biosciences announced data that demonstrated sustained benefit of its once-weekly Canvuparatide as a potential PTH replacement therapy in chronic hypoparathyroidism